485 related articles for article (PubMed ID: 28866094)
21. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.
Yoshida A; Lee EK; Diehl JA
Cancer Res; 2016 May; 76(10):2990-3002. PubMed ID: 26988987
[TBL] [Abstract][Full Text] [Related]
22. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Takahashi O; Komaki R; Smith PD; Jürgensmeier JM; Ryan A; Bekele BN; Wistuba II; Jacoby JJ; Korshunova MV; Biernacka A; Erez B; Hosho K; Herbst RS; O'Reilly MS
Clin Cancer Res; 2012 Mar; 18(6):1641-54. PubMed ID: 22275507
[TBL] [Abstract][Full Text] [Related]
23. Palbociclib overcomes afatinib resistance in non-small cell lung cancer.
Nie H; Zhou X; Shuzhang D; Nie C; Zhang X; Huang J
Biomed Pharmacother; 2019 Jan; 109():1750-1757. PubMed ID: 30551429
[TBL] [Abstract][Full Text] [Related]
24. Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.
Green JL; Okerberg ES; Sejd J; Palafox M; Monserrat L; Alemayehu S; Wu J; Sykes M; Aban A; Serra V; Nomanbhoy T
Mol Cancer Ther; 2019 Apr; 18(4):771-779. PubMed ID: 30837298
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in
Fanini F; Bandini E; Plousiou M; Carloni S; Wise P; Neviani P; Murtadha M; Foca F; Fabbri F; Vannini I; Fabbri M
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948154
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and Biological Evaluation of Novel
Song X; Gan Q; Zhang X; Zhang J
Mol Pharm; 2019 Oct; 16(10):4213-4222. PubMed ID: 31424939
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
Lopes-Ventura S; Pojo M; Matias AT; Moura MM; Marques IJ; Leite V; Cavaco BM
J Endocrinol Invest; 2019 May; 42(5):527-540. PubMed ID: 30191474
[TBL] [Abstract][Full Text] [Related]
28. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
[TBL] [Abstract][Full Text] [Related]
29. Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer.
Cao J; Zhu Z; Wang H; Nichols TC; Lui GYL; Deng S; Rejto PA; VanArsdale T; Hardwick JS; Weinrich SL; Wei P
Oncogene; 2019 May; 38(21):4125-4141. PubMed ID: 30700828
[TBL] [Abstract][Full Text] [Related]
30. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
Ku BM; Yi SY; Koh J; Bae YH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Oncotarget; 2016 Mar; 7(12):14803-13. PubMed ID: 26909611
[TBL] [Abstract][Full Text] [Related]
31. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
[TBL] [Abstract][Full Text] [Related]
32. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma.
Nassar KW; Hintzsche JD; Bagby SM; Espinoza V; Langouët-Astrié C; Amato CM; Chimed TS; Fujita M; Robinson W; Tan AC; Schweppe RE
Mol Cancer Ther; 2021 Oct; 20(10):2049-2060. PubMed ID: 34376578
[TBL] [Abstract][Full Text] [Related]
33. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
Liu M; Xu S; Wang Y; Li Y; Li Y; Zhang H; Liu H; Chen J
Oncotarget; 2016 Dec; 7(51):84951-84964. PubMed ID: 27825114
[TBL] [Abstract][Full Text] [Related]
34. CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.
Wright GM; Gimbrone NT; Sarcar B; Percy TR; Gordián ER; Kinose F; Sumi NJ; Rix U; Cress WD
PLoS One; 2021; 16(6):e0252927. PubMed ID: 34138895
[TBL] [Abstract][Full Text] [Related]
35. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
Carter CA; Rajan A; Keen C; Szabo E; Khozin S; Thomas A; Brzezniak C; Guha U; Doyle LA; Steinberg SM; Xi L; Raffeld M; Tomita Y; Lee MJ; Lee S; Trepel JB; Reckamp KL; Koehler S; Gitlitz B; Salgia R; Gandara D; Vokes E; Giaccone G
Ann Oncol; 2016 Apr; 27(4):693-9. PubMed ID: 26802155
[TBL] [Abstract][Full Text] [Related]
36. Selumetinib for the treatment of non-small cell lung cancer.
Casaluce F; Sgambato A; Maione P; Sacco PC; Santabarbara G; Gridelli C
Expert Opin Investig Drugs; 2017 Aug; 26(8):973-984. PubMed ID: 28675058
[TBL] [Abstract][Full Text] [Related]
37. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
Jänne PA; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios C; Franke FA; Grinsted L; Zazulina V; Smith P; Smith I; Crinò L
Lancet Oncol; 2013 Jan; 14(1):38-47. PubMed ID: 23200175
[TBL] [Abstract][Full Text] [Related]
38. An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.
Teh JL; Purwin TJ; Greenawalt EJ; Chervoneva I; Goldberg A; Davies MA; Aplin AE
Cancer Res; 2016 Sep; 76(18):5455-66. PubMed ID: 27488531
[TBL] [Abstract][Full Text] [Related]
39. Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.
Long Q; Ma AH; Zhang H; Cao Z; Xia R; Lin TY; Sonpavde GP; de Vere White R; Guo J; Pan CX
Cancer Immunol Immunother; 2020 Nov; 69(11):2305-2317. PubMed ID: 32506263
[TBL] [Abstract][Full Text] [Related]
40. Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway.
von Witzleben A; Goerttler LT; Marienfeld R; Barth H; Lechel A; Mellert K; Böhm M; Kornmann M; Mayer-Steinacker R; von Baer A; Schultheiss M; Flanagan AM; Möller P; Brüderlein S; Barth TF
Cancer Res; 2015 Sep; 75(18):3823-31. PubMed ID: 26183925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
